What is the clinical evidence from this study?

Population: atrial fibrillation.

What does this research mean for the field?

In patients with atrial fibrillation and a CHADS2 score of 1, treatment with an oral anticoagulant, but not an antiplatelet agent, is independently associated with a significantly decreased risk of death or stroke. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether oral anticoagulant therapy provides greater clinical benefit than antiplatelet therapy in patients with atrial fibrillation and an intermediate thromboembolic risk defined by a CHADS2 score of 1.

January 1, 2010Thrombosis and Haemostasis

Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

View Full Paper

Ask AI

Bookmark

Key result

No clinical data is available in the provided text, which consists only of journal editorial board information.

Why the study?

Does oral anticoagulant reduce death or stroke in patients with atrial fibrillation and a CHADS2 score of 1?

Key Points

To determine whether oral anticoagulant therapy provides greater clinical benefit than antiplatelet therapy in patients with atrial fibrillation and an intermediate thromboembolic risk defined by a CHADS2 score of 1.
Analyzed an unselected cohort of 6,517 patients with atrial fibrillation, identifying 1,012 patients with a CHADS2 score of 1 eligible for antithrombotic therapy.
Tracked outcomes for patients prescribed oral anticoagulants (N=606, 59.9%) versus antiplatelet therapy or no treatment (N=406, 40.1%) over a median follow-up of 793 days (interquartile range: 1,332 days).
Over the follow-up period, 105 total deaths (10.4%) and 19 strokes (1.9%) occurred across the cohort.
Oral anticoagulant therapy was associated with a significant decrease in death and stroke events compared to no anticoagulant use (RR 0.42, 95% CI 0.29–0.60, p<0.0001), persisting after adjustment for age and confounders.
Prescription of an antiplatelet agent showed no protective effect against events, whereas older age (p<0.0001), heart failure (p=0.0002), diabetes (p=0.0025), permanent AF (p=0.04), and lack of anticoagulant use independently predicted adverse outcomes.

Structured PICO

Does oral anticoagulant reduce death or stroke in patients with atrial fibrillation and a CHADS2 score of 1?

Population

1,012 unselected patients with atrial fibrillation (AF) and a CHADS2 score of 1

Intervention

Oral anticoagulant

Comparator

Antiplatelet agent or no antithrombotic treatment

Outcome

Composite of death or strokehard clinical

In patients with atrial fibrillation and a CHADS2 score of 1, oral anticoagulation is associated with a significantly lower risk of death or stroke compared to antiplatelet therapy or no treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Associated with lower death/stroke risk in CHADS2=1 AF; leaves open randomized confirmation before practice change.

Cite This Study

Gorin et al. (2010) studied atrial fibrillation. No clinical data is available in the provided text, which consists only of journal editorial board information.

synapsesocial.com/papers/6a1d8a03cc9f7df1b7059809 https://doi.org/10.1160/th09-10-0746

Topics

Atrial fibrillation Heart failure HFrEF treatment Persistent AF management Anticoagulation in AF Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider